A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...

Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

Not letting its expansion efforts idle, contract manufacturer PCI Pharma Services is picking up a 100% stake in Ajinomoto's ...

When Roy Bradley was told he had cancer in his lungs and liver, his first thought was he couldn't face chemotherapy and ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to ...

Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patie ...